- Home
- PRTG vs XAIR Comparison
PRTG vs XAIR Comparison
Compare PRTG & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTG
- XAIR
- Stock Information
- Founded
- PRTG 1973
- XAIR 2011
- Country
- PRTG British Virgin Islands
- XAIR United States
- Employees
- PRTG N/A
- XAIR N/A
- Industry
- PRTG Oil & Gas Production
- XAIR Medical/Dental Instruments
- Sector
- PRTG Energy
- XAIR Health Care
- Exchange
- PRTG Nasdaq
- XAIR Nasdaq
- Market Cap
- PRTG 17.7M
- XAIR 17.0M
- IPO Year
- PRTG N/A
- XAIR N/A
- Fundamental
- Price
- PRTG $8.85
- XAIR $3.16
- Analyst Decision
- PRTG
- XAIR Strong Buy
- Analyst Count
- PRTG 0
- XAIR 3
- Target Price
- PRTG N/A
- XAIR $23.67
- AVG Volume (30 Days)
- PRTG 44.3K
- XAIR 388.4K
- Earning Date
- PRTG 08-26-2025
- XAIR 08-12-2025
- Dividend Yield
- PRTG N/A
- XAIR N/A
- EPS Growth
- PRTG N/A
- XAIR N/A
- EPS
- PRTG N/A
- XAIR N/A
- Revenue
- PRTG N/A
- XAIR $3,705,000.00
- Revenue This Year
- PRTG N/A
- XAIR $266.61
- Revenue Next Year
- PRTG N/A
- XAIR $140.76
- P/E Ratio
- PRTG N/A
- XAIR N/A
- Revenue Growth
- PRTG N/A
- XAIR 219.67
- 52 Week Low
- PRTG $2.10
- XAIR $2.73
- 52 Week High
- PRTG $23.01
- XAIR $13.52
- Technical
- Relative Strength Index (RSI)
- PRTG 65.34
- XAIR 48.77
- Support Level
- PRTG $8.08
- XAIR $2.75
- Resistance Level
- PRTG $10.25
- XAIR $2.95
- Average True Range (ATR)
- PRTG 0.87
- XAIR 0.20
- MACD
- PRTG 0.43
- XAIR 0.02
- Stochastic Oscillator
- PRTG 71.72
- XAIR 55.13
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.